Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Kare Chemical Technologies Inc. maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The data indicates 1 pending office action currently active. BORALSKY, LUKE ALAN is the busiest examiner and is responsible for the pending office action.
The prosecution environment is centralized, involving 1 distinct examiner and a distinct art unit. Because BORALSKY, LUKE ALAN manages the workload, the company's success in this matter depends on addressing the specific concerns of this examiner. This structure simplifies the management of the portfolio by focusing on a point of contact at the patent office.
The presence of a distinct art unit suggests that the pending application falls within a specific technical niche. Practitioners should focus on the examiner's previous rulings and preferences to navigate the prosecution process. Since there is a pending office action, the resolution of this case will be a primary driver of the portfolio's immediate growth and success.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558674 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | BORALSKY, LUKE ALAN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18558674 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | BORALSKY, LUKE ALAN | 1624 | §103 | Final Rejection | — | Pending | Nov 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKare Chemical Technologies Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Luke Alan Boralsky has the most, with 1 of Kare Chemical Technologies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
